SCHEMBL770691

SCHEMBL770691

[CH2]C(=O)N1CCCCCC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
HPGD P15428 3/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
MMP9 P14780 1/20 0.46
CA2 P00918 2/20 0.44
CHKA P35790 1/20 0.44
ATM Q13315 1/20 0.42
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
F2 P00734 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
GAA P10253 1/20 0.39
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771905 1.00 ALDH1A1 (0.55) ALDH1A1HPGDMMP1MMP2MMP3
SCHEMBL773224 1.00 ALDH1A1 (0.55) ALDH1A1HPGDMMP1MMP2MMP3
SCHEMBL425387 1.00
SCHEMBL295072 0.97
SCHEMBL208938 0.90
SCHEMBL1196794 0.83
SCHEMBL422889 0.77 L3MBTL3 (0.58) ALDH1A1MEN1KMT2A
SCHEMBL1197205 0.76 CYP1A2 (0.52) ALDH1A1HPGDMEN1KMT2A
SCHEMBL15750610 0.75 CA2 (0.56) CA2CHKAPOLBCA12CA1
SCHEMBL771350 0.75 HTT (0.55) ALDH1A1POLBHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-09-13 US disclosed
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-07-17 US disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
EP-2206715-A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor Japan Tobacco, Inc. (JP) 2010-07-14 EP disclosed
US-7659263-B2 Thienopyrrole compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2010-02-09 US disclosed
EP-1719773-B1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC (JP) 2009-04-15 EP disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
EP-1719773-A1 FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2006-11-08 EP disclosed
US-20060167246-A1 Thienopyrrole compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2006-07-27 US disclosed
US-4049658-A N'-substituted derivatives of 4'-(N-piperazinylmethyl) spiro dibenzocycloheptadi- (or tri-) ene-5, 2'-dioxolane (1',3') their method of preparation and their application in therapeutics DELALANDE S.A. (FR) 1977-09-20 US disclosed
US-4049660-A N-substituted derivatives of 4 (N-piperazinylmethyl) spiro dibenzocycloheptadi- (or tri-) ene-5, 2-dioxolane (1,3) their method of preparation and their application in therapeutics DELALANDE S.A. (FR) 1977-09-20 US disclosed
US-4048164-A ANALGESICS, HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, ANTIARYTHMIC DELALANDE S.A. (FR) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 ALDH1A1 750/4885HPGD 2752/4885MMP1 1807/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-20060167246-A1 Thienopyrrole compound and use thereof as HCV polymerase inhibitor TPMT, JAK2, GTF3C5 ALDH1A1 351/4885HPGD 1292/4885MMP1 3725/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-20180258089-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-10023573-B2 Beta-lactamase inhibitor and process for preparing the same FN1, FNTB, CPN1 ALDH1A1 495/4885HPGD 1334/4885MMP1 68/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 ALDH1A1 495/4885HPGD 1334/4885MMP1 68/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 ALDH1A1 1362/4885HPGD 1998/4885MMP1 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.